GeneGlobe ID: JHS-004Z | Cat. No.: | QIAseq RNA Fusion XP Panels

QIAseq RNA Fusion XP Lymphoma Panel

Kit containing ALL reagents (except indexes) for fusion and gene expression profiling by digital RNAseq

Select a variant to see the price

Product Specification

Target List

Covers specific sides of specific exons of the targeted genes based on the Human GRCh38 genome build.Analyzes the expression of the targeted genes.Covers specific hotspots of the targeted genes based on the Human GRCh38 genome build.

Acute Lymphoblastic Lymphomas
CREBBP (CBP), KMT2A, MLLT10, MYC, P2RY8, PRDM16, STIL
Anaplastic Large Cell Lymphomas
ADGRG7, ALK, ATIC, CLTC, MSN, MYC, NPM1, TFG, TPM3, TPM4, ALK, CDKN2A (P16INK4A), DNMT3A, NRAS, STAT3
Angioimmunoblastic T Cell Lymphomas
CD28, CTLA4, FIP1L1, PDGFRA, ALK, APC, ARID1A, ASXL1, ATM, BRAF, CDKN2A (P16INK4A), CREBBP (CBP), CTNNB1, DNMT3A, EZH2, FBXW7, IDH2, JAK1, JAK3, KIT (CD117), KMT2D, KRAS, MED12, PLCG1, RHOA, STAT3, WT1, XPO1, ZFHX3
Burkitt Lymphomas
BCL6, MYC, PBX1, TCF3, APC, ARID1A, ATM, CD79B, CDKN2A (P16INK4A), CREBBP (CBP), FBXW7, HLA-A, ID3, KRAS, MYC, MYD88, NRAS, PAX5, PIK3CA (p110-alpha), PIK3R1 (p85-ALPHA), PTEN, RHOA, SRSF2
Diffuse Large B Cell Lymphomas (DLBCL)
ALK, BCL11A, BCL6, CCND3, CIITA, CLTC, IGLL5, MAPK13 (p38delta), MYC, NPM1, PIM1, REL, SQSTM1, TBL1XR1, TOMM40, TP63, ALK, AMER1, APC, ARID1A, ASXL1, ATM, B2M, BCL2, BCOR, BRAF, BTK, CD79B, CDKN2A (P16INK4A), CNOT3, CREBBP (CBP), CTNNB1, CXCR4, DNMT3A, EZH2, FBXW7, HLA-A, ID3, IDH2, IRS4, JAK1, JAK3, KIT (CD117), KMT2D, KRAS, MAP2K1, MED12, MSN, MYC, MYD88, NCOR1, NFKBIE, NOTCH2, NRAS, NSD2, PAX5, PIK3CA (p110-alpha), PIK3R1 (p85-ALPHA), PLCG1, POT1, PPM1D, PTEN, RGS7, RHOA, SF3B1, SMO, SRSF2, STAT3, STAT5B, STAT6, TERT, TRRAP, WT1, XPO1, ZFHX3, ZNF479
Follicular Lymphomas
AFF3, BCL2, BCL6, CIITA, MYC, TBL1XR1, TP63, AMER1, ARID1A, ATM, B2M, BCL2, BCOR, BRAF, BTK, CD79B, CDKN2A (P16INK4A), CREBBP (CBP), CXCR4, DNMT3A, EZH2, FBXW7, ID3, IDH2, KMT2D, MAP2K1, MED12, MYD88, NOTCH2, NRAS, PIK3R1 (p85-ALPHA), PPM1D, PTEN, RGS7, RHOA, SRSF2, STAT6, ZMYM3
Hodgkin Lymphomas
ALK, CIITA, JAK2, NPM1, SEC31A, ARID1A, ASXL1, B2M, BCOR, CDKN2A (P16INK4A), DNMT3A, EZH2, NFKBIE, NRAS, PAX5, PIK3R1 (p85-ALPHA), PPM1D, SF3B1
Inflammatory Myofibroblastic Tumors
ALK, DCTN1
Lymphoblastic Lymphomas
BCR, ETV6, FGFR1, NOTCH1, PBX1
Lymphoblastic T Cell Lymphomas
BCR, ETV6, FGFR1, FIP1L1, LYN, PDGFRA
Mantle Cell Lymphomas
CCND3, MYC, ARID1A, ASXL1, ATM, B2M, BCOR, BRAF, BTK, CDKN2A (P16INK4A), CREBBP (CBP), DNMT3A, IDH2, KMT2D, KRAS, MED12, NCOR1, NFKBIE, NOTCH2, NRAS, NSD2, PAX5, POT1, PPM1D, PTEN, STAT3, TERT, ZFHX3
Mediastinal Large B Cell Lymphomas (MLBL)
CIITA, PDCD1LG2
Mediastinal Large B-Cell Lymphomas
CIITA, PDCD1LG2
Mucosa-Associated Lymphoid Tissue (MALT) Lymphomas
BCL6, BIRC3 (c-IAP2), CCND3, MALT1, MYC, MYD88, NOTCH2
Peripheral T Cell Lymphomas
ALK, ETV6, FGFR3, ITK, MYO1F, NPM1, S100A7, SYK, TBL1XR1, THAP4, TP63, VAV1, ALK, ARID1A, ASXL1, ATM, CDKN2A (P16INK4A), CTNNB1, DNMT3A, IDH2, IRS4, KIT (CD117), KMT2D, KRAS, MAP2K1, MSN, NRAS, PLCG1, PTEN, RGS7, RHOA, STAT3, STAT5B, TRRAP, XPO1, ZFHX3, ZNF479
Precursor T Cell Lymphoblastic Lymphomas
ABL1, JAK2, NUP214, PCM1, SET, CTNNB1, FBXW7, NRAS, WT1
T Cell Lymphomas
ATXN2L, FGFR1, JAK2
Other Lymphomas
ALK, ATXN2L, BCL6, BIRC3 (c-IAP2), CBFB, CCND1, CCND3, CDK6, CHIC2, CLTC, DEK, DUSP22, EIF4A1, JAK2, KMT2A, MALT1, MKL1, MLF1, MLLT10, NFKB2, NPM1, PRDM16
Commercial Control Samples
ALK, BAIAP2L1, BRAF, CCDC6, CD74, EGFR (ERBB1), EML4, ERG, ETV6, FGFR3, KIF5B, LMNA, MET, NCOA4, NTRK1, NTRK3, PAX8, PPARG, RET, ROS1, SEPT14, SLC34A2, SLC45A3, TACC3, TFG, TMPRSS2, TPM3
Checkpoint Molecules
Inhibitory on Tumor Cells​
CD200, CD274 (PD-L1), CD274 (PD-L1), CD48, CD80, CD86, ITGAV, ITGB3, LGALS9, MICA, MICB, PDCD1LG2, TNFRSF14, VSIR
Stimulatory on Tumor Cells​
CD40 (TNFRSF5), CD40LG, CD48, CD70, CD86, ICOSLG, TNFRSF9, TNFSF14, TNFSF4 (OX40L), TNFSF9
Inhibitory on T Cells​
BTLA, CD160, CD200R1, CD244, CD274 (PD-L1), CD274 (PD-L1), CD28, CTLA4, HAVCR2, KLRC1, LAG3, LILRB1, LILRB3, PDCD1 (PD1), PDCD1 (PD1), VSIR
Stimulatory on T Cells​
CD244, CD27 (TNFRSF7), CD28, CD40 (TNFRSF5), CD40LG, ICOS, TNFRSF14, TNFRSF18, TNFRSF4 (OX40), TNFRSF9, TNFSF14, TNFSF9
T Cell Receptor Genes​
CD247, CD3D, CD3E, CD3G, TRAC, TRGC2
Major Histocompatibility Complex I Genes​
B2M, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, MR1
Major Histocompatibility Complex II Genes​
CD74, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRA, HLA-DRB1, HLA-DRB5, IFI30
Other Checkpoint Molecules​
ADORA2A, BTNL2, CD160, CD276, CD44, CD52, CD8A, HHLA2, IDO1 (IDO), IDO1 (IDO), IDO2, KIR3DL1, KLRD1, LAIR1, MS4A1, NRP1, TIGIT, TMIGD2, TNFRSF25 (DR3), TNFRSF8, TNFSF15, VTCN1
Checkpoint Blockade Therapy Biomarkers
BTLA, CD274 (PD-L1), CD274 (PD-L1), CD80, CD8A, CSF2 (GM-CSF), CXCL11 (I-TAC, IP-9), HAVCR2, HLA-DRA, HLA-DRB1, HLA-DRB5, ICOS, IFNG, LAG3, PDCD1 (PD1), PDCD1 (PD1), PDCD1LG2
Immuno Regulatory Gene Signature
ERBB2 (HER-2, NEU), FAS, IL5RA (CD125), INHBA, TNFRSF8, TNFSF4 (OX40L), TNFSF9
Immuno Stimulatory Gene Signature
CD160, CD19, CD200, CD27 (TNFRSF7), CD44, CTLA4, HLA-A, IL12RB2, IL17A, KIT (CD117), TNFRSF17
Immuno Suppressive Gene Signature
CD274 (PD-L1), CD274 (PD-L1), CD276, HAVCR2, PDCD1LG2, TGFB1
Upregulated in Cancer Vaccination Response
CCL5 (RANTES), CD3D, CD86, CD8A, CXCL10 (INP10), CXCL9 (MIG), GBP1, ICOS, IRF1, KLRD1, PSMB9, STAT1
Immune Cell Markers
CD8 T Cells​
CD8A, CD8B, FLT3LG, GZMM, PRF1
Th1 Cells​
CCL4 (MIP-1B), CD38, CD70, CSF2 (GM-CSF), CTLA4, DPP4, IFNG, IL12RB2, LTA (TNFB), STAT4, TBX21
Th17 Cells​
IL17A, IL17RA, RORC
Th2 Cells​
CXCR6, GATA3, IL26, LAIR2, MAF, PMCH, SMAD2 (MADH2), STAT6
Follicular Helper T Cells​
BCL6, CXCL13, MAF, PDCD1 (PD1), PDCD1 (PD1)
Other T Helper Cell Markers​
ANP32B, BATF, CD28, ICOS, NUP107
Regulatory T Cells​
FOXP3
Gamma Delta T Cells​
CD160, FEZ1, TRGC1
Central Memory T Cells​
ATM, DOCK9, FYB1, NEFL, REPS1, TXK, USP9Y
Effector Memory T Cells​
AKT3, CCR2, EWSR1, IL15RA, LTK, NFATC4 (NFAT3)
Other T Cell Markers​
CD2, CD247, CD3D, CD3E, CD3G, CD6, IL2RB, TNFRSF25 (DR3), TRAC, TRGC2
Myeloid Derived Suppressor Cells​
TGFB1
Cytotoxic Lymphocytes​
CD3E, CD3G, CD8A, CD8B, EOMES, GZMA, GZMB, IFNG, KLRC1, KLRD1, NKG7, TBX21
Natural Killer Cells​
BCL2, CD160, FOXJ1, FUT5, GTF3C1, GZMB, IL21R, KIR3DL1, MPPED1, NCR1, PLA2G6, RRAD, ZNF205
Activated Dendritic Cells​
CCL1 (I-309), EBI3, LAMP3, OAS3
Immature Dendritic Cells​
CD1A, CD1B, CD1E, F13A1, SYT17
Myeloid Dendritic Cells​
CD1A, CD1B, CD1E
Plasmacytoid Dendritic Cells​
IL3RA
Other Dendritic Cell Markers​
CCL13 (MCP-4), CCL17 (TARC), CCL22 (MDC), CD209, HSD11B1
Macrophages​
APOE, CCL7 (MCP-3), CD68, CHIT1, CXCL5 (ENA-78, LIX), MARCO, MSR1
Neutrophils​
CSF3R (GM-CSFR), FPR2, MME
Eosinophils​
CCR3, IL5RA (CD125), PTGDR2 (CRTH2, GPR44), SMPD3, THBS1 (TSP-1)
Mast Cells​
CMA1, CTSG, KIT (CD117), MS4A2, PRG2, TPSAB1
B Cells​
BANK1, BLK, CD19, CD79A, CR2, HLA-DOB, HLA-DQA1, MS4A1, PAX5, TNFRSF17
Antigen Presenting Cells​
CMKLR1
Regulatory T Cell Gene Signature
CD274 (PD-L1), CD274 (PD-L1), JAK1, PDCD1LG2, TIGIT, TNFRSF18, TNFRSF4 (OX40), TNFRSF8, TNFRSF9
T Cell Trafficking & Infiltration into Tumors
Stimulates T Cell Trafficking & Infiltration into Tumors​
CCL5 (RANTES), CX3CL1, CXCL10 (INP10), CXCL9 (MIG), ITGB2, SELL (LECAM-1)
Other T Cell Trafficking & Infiltration into Tumors Genes​
CCL17 (TARC), CCL4 (MIP-1B), CCR3, CCR6, CD274 (PD-L1), CD274 (PD-L1), CD44, CSF2 (GM-CSF), CXCL11 (I-TAC, IP-9), CXCL13, FOXP3, IFNG, ITGA4 (CD49D), ITGB7, LTA (TNFB), PDCD1 (PD1), PDCD1 (PD1), PDCD1LG2, PTEN, TNFRSF25 (DR3), TNFSF14
T Cell Exhaustion
Upregulated in T Cell Exhaustion​
CCL5 (RANTES), CD200, CD27 (TNFRSF7), CD69, CTLA4, CXCL10 (INP10), CXCL13, GBP1, HLA-DMA, HLA-DQA1, ICOS, IFI16, IFNG, ITGAV, TAP1 (ABCB2), TIGIT, TNFRSF9
Downregulated in T Cell Exhaustion​
TNFRSF25 (DR3)
T Cell Exhaustion Transcriptional Nodes​
BATF, TBX21
Responsiveness or Response Biomarkers
Enhanced Expression in Responsive Versus Nonresponsive Cancers​
APP, CAPZB, CCL4 (MIP-1B), CCL5 (RANTES), CD8A, CSNK1E, CTLA4, CXCL10 (INP10), CXCL11 (I-TAC, IP-9), CXCL9 (MIG), EBI3, EHD1, GBA2, GZMB, HLA-DQA1, IDO1 (IDO), IDO1 (IDO), IFNG, INHBA, IRF2, NKG7, ODF2, PHKG2, PPIF, PRF1, SERPINA3, SHMT2, SIGMAR1, SMAD3 (MADH3), TIA1
Suppressed Expression in Responsive Versus Nonresponsive Cancers​
ACTG1, BNIP3L, CX3CL1, FOXN3, IFI27, JAK1, LTA4H, NAIP, OPTN, PRRC2B, PTEN, RBL2, TXK
Differentially Expressed in Responsive Versus Nonresponsive Cancers​
ADAM28, AKNA, AOAH, ARHGAP9, CACNA2D2, CARD11, CARD16, CD109, CLEC11A, CORO1A, CORO1B, CXCR4, FLT3, FMNL1, HIVEP1, HIVEP2, IFI44L, IFITM1 (9-27), IGHA1, IGHM, IGSF6, IKZF1, ITPKA, LSM4, LST1, MAP3K14, NFAM1, NFKBIL1, PLA2G2D, POU2AF1 (OCA-B), PTPRCAP, SERPINB9, SH3BP5, SYTL1, TMC8, TNFRSF13B, TNFRSF19, ZFYVE9
Expression Correlates with Positive Objective Response Rates​
CD274 (PD-L1), CD274 (PD-L1), CD276, CTLA4, HAVCR2, IDO1 (IDO), IDO1 (IDO), LAG3, PDCD1LG2, VTCN1
Upregulated during Treatment​
CD8A, CTLA4, CXCL10 (INP10), EOMES, GZMA, GZMB, ICOS, IFNG, PRF1
Regulated during Treatment​
IRF1
Pre-Treatment Response Prediction
Predicts Enhanced Response​
ADAM17 (CD156B), MYC, RHOC, TIMP1
Other Pre-Treatment Response Predictors​
CDK2, CDKN2A (P16INK4A), LARGE1, NAB2, NRAS
Cancer Cell Killing
Inhibits Cancer Cell Killing​
BTLA, CD274 (PD-L1), CD274 (PD-L1), CD80, HAVCR2, IDO1 (IDO), IDO1 (IDO), IDO2, LAG3, MICA, MICB, PDCD1 (PD1), PDCD1 (PD1), TGFB1, VSIR, VTCN1
Stimulates Cancer Cell Killing​
IFNG
Antigen Processing & Presentation
Proteasome​
PSMB10, PSMB9
Proteases​
IFI30
Endoplasmic Reticulum & Lysosomal Transport​
TAP1 (ABCB2), TAP2 (ABCB3), TAPBPL
Major Histocompatibility Complex I Genes​
B2M, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, MR1
Major Histocompatibility Complex II Genes​
CD74, HLA-DMA, HLA-DQA1, HLA-DRA, HLA-DRB1, HLA-DRB5, IFI30
Immune Cell Receptors & Co-Receptors​
CD8A, CD8B, KIR3DL1, KLRC1, KLRD1
Stimulates Antigen Presentation​
CD40 (TNFRSF5), CD40LG
Interferon Gamma Response
Cytokines & Chemokines​
CCL5 (RANTES), IL15RA, STAT1
Major Histocompatibility Complex I Genes​
B2M, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H
Major Histocompatibility Complex II Genes​
HLA-DMA, HLA-DQA1, HLA-DRA, HLA-DRB1, HLA-DRB5, IFI30
RNA Degradation​
OAS3
Transcription Factors​
IRF1, IRF2
Other Interferon Gamma Response Genes​
CD44, GBP1
Cytosolic DNA-Sensing Pathway
Cytokines & Interferons​
CCL4 (MIP-1B), CCL5 (RANTES), CXCL10 (INP10)
Expression Altered due to Genetic Alterations
BCL10, BCL2, BCL3, BCL6, BCL9, CCND1, CCND2, CCND3, CD44, CDK6, ERVW-1, FCGR2B, FCRL4, FOXP1, GPR34, IRF4, KDSR, MALT1, MTCP1, MUC1 (mucin), MYC, NBEAP1, NFKB2, PAX5, PRDM16
AIDS-Related Lymphomas
EZH2
B Cell Lymphomas
ARID1A, ATM, B2M, BCL2, BCOR, BRAF, CD79B, CDKN2A (P16INK4A), CREBBP (CBP), CTNNB1, CXCR4, DNMT3A, EZH2, JAK3, KIT (CD117), KMT2D, MAP2K1, MYD88, PIK3CA (p110-alpha), PPM1D, PTEN, RHOA, STAT3
Small Lymphocytic Lymphomas
ALK, APC, ARID1A, ASXL1, ATM, BCL2, BCOR, BRAF, BTK, CD79B, CDKN2A (P16INK4A), CNOT3, CREBBP (CBP), CXCR4, DNMT3A, FBXW7, GNAS, IRS4, JAK1, JAK3, KIT (CD117), KMT2D, KRAS, MAP2K1, MED12, MSN, MYC, MYD88, NCOR1, NFKBIE, NOTCH2, NRAS, PAX5, PIK3CA (p110-alpha), PIK3R1 (p85-ALPHA), PLCG1, POT1, PPM1D, PTEN, RGS7, SF3B1, STAT5B, STAT6, TERT, TRRAP, XPO1, ZFHX3, ZMYM3, ZNF479
Cutaneous T Cell Lymphomas
KRAS, PTEN
Diffuse Red Pulp Small B Cell Lymphomas
MYD88, NOTCH2
Enteropathy-Type T Cell Lymphomas
STAT5B
Gamma-Delta T Cell Lymphomas
STAT3, STAT5B
Hepatosplenic T Cell Lymphomas
STAT3, STAT5B
Lymphoplasmacytic Lymphomas
ARID1A, BTK, CD79B, CXCR4, DNMT3A, MYD88
Marginal Zone Lymphomas
AMER1, ARID1A, ASXL1, ATM, BRAF, CD79B, CREBBP (CBP), CXCR4, DNMT3A, EZH2, FBXW7, GNAS, JAK3, KIT (CD117), KMT2D, MAP2K1, MYD88, NFKBIE, NOTCH2, PIK3R1 (p85-ALPHA), RHOA, SRSF2, TRRAP, XPO1
Mycosis Fungoides (Sezary Syndrome)
AMER1, ARID1A, ATM, BCOR, CDKN2A (P16INK4A), DNMT3A, JAK1, JAK3, KMT2D, KRAS, NCOR1, NRAS, PIK3CA (p110-alpha), PLCG1, POT1, PTEN, STAT3, STAT5B
NK-T Cell Lymphomas
ALK, AMER1, APC, ARID1A, ASXL1, ATM, B2M, BCOR, BRAF, CTNNB1, DNMT3A, EZH2, FBXW7, HLA-A, JAK1, JAK3, KIT (CD117), KMT2D, KRAS, MED12, NCOR1, NOTCH2, NRAS, POT1, RGS7, RHOA, SMO, STAT3, STAT5B, WT1, XPO1, ZFHX3
Primary Central Nervous System Lymphomas
B2M, BCL2, CD79B, CDKN2A (P16INK4A), CXCR4, DNMT3A, HLA-A, JAK3, KIT (CD117), KRAS, MYD88, NOTCH2, POT1, STAT3, STAT5B, TERT, TRRAP, WT1
Primary Effusion Lymphomas
CDKN2A (P16INK4A), PTEN

Product Resources

Detailed Target List for each Analyte
File Size: 25.78 KBLanguage: English

Resources

Safety Data Sheets (1)
Kit Handbooks (1)
Template Files (1)
Certificates of Analysis (1)
Introducing the QIAseq RNA Fusion XP Lymphoma Panel, a cutting-edge addition to our QIAseq RNA Fusion XP Panels lineup, specifically designed for {{application}} applications. This premium product offers unparalleled performance for researchers working with Human models. Leveraging advanced technology, the QIAseq RNA Fusion XP Lymphoma Panel facilitates accurate and reliable results, making it an indispensable tool for your scientific investigations. Whether you're conducting {{application}}, or any other sophisticated analyses, this product from our QIAseq RNA Fusion XP Panels collection ensures optimal efficiency and reproducibility for Human studies. Embrace the future of research with QIAseq RNA Fusion XP Lymphoma Panel and elevate your work to new heights.